AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript

Pamela Palmer: Yes, they’re looking at basically the filter life span — so we anticipate, obviously, when you’re profusing saline into the circuit and you’re not inhibiting quoting that those filters lot much more frequently. And they’re also looking at platelets, a number of transfusions how efficient the dialysis is looking at urea concentrations, et cetera. So there’s just a whole host of key secondary endpoints that are clinically important, but the primary end point again being activated clotting time over the first 24 hours of a powerful anticoagulant versus placebo, we feel pretty confident in that.

Vincent Angotti: And I think you asked about timing, Laura. Again, we’re just guiding to the second half of this year. Dr. Palmer team are working with the CROs as we sit here now based off selection sites, et cetera. So again, we’re excited to get that one going as quickly as we can.

Unidentified Analyst: Got it. Thank you, for taking my question.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Vince Angotti for any closing remarks.

Vincent Angotti: Thanks, Andrew, and thank you for all of you for joining us today and for your continued support of AcelRx. We’re really excited about our execution on the stated plan. the significant progress we continue to make with Niyad and our prefilled syringes, in particular, Fed Sera. And we look and remain focused on driving long-term shareholder value with advancing this high-value, late-stage pipeline. I look forward to answering any additional questions you might have offline and sharing our future developments with you. Again, thank you for your attendance, and please be safe.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.